Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177


Outcomes of localized prostate cancer following conservative management.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL.

JAMA. 2009 Sep 16;302(11):1202-9. doi: 10.1001/jama.2009.1348.


Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.


Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. Erratum in: JAMA. 2009 Jan 7;301(1):38.


Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.


20-year outcomes following conservative management of clinically localized prostate cancer.

Albertsen PC, Hanley JA, Fine J.

JAMA. 2005 May 4;293(17):2095-101.


Fifteen-year survival outcomes following primary androgen-deprivation therapy for localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA Intern Med. 2014 Sep;174(9):1460-7. doi: 10.1001/jamainternmed.2014.3028.


Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.

J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.


Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.

D'Amico AV, Renshaw AA, Sussman B, Chen MH.

JAMA. 2005 Jul 27;294(4):440-7.


Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.


Prostate-specific antigen surveillance among men with clinically localized prostate cancer who do not receive initial treatment.

Yeboa DN, Guzzo T, Mitra N, Christodouleas JP, Haas NB, Vapiwala N, Armstrong K, Bekelman JE.

Urology. 2011 Nov;78(5):1107-13. doi: 10.1016/j.urology.2011.04.069. Epub 2011 Sep 23.


Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD.

JAMA. 1999 May 5;281(17):1598-604.


Survival associated with treatment vs observation of localized prostate cancer in elderly men.

Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, Montagnet C, Armstrong K.

JAMA. 2006 Dec 13;296(22):2683-93. Erratum in: JAMA. 2007 Jan 3;297(1):42.


Five-year downstream outcomes following prostate-specific antigen screening in older men.

Walter LC, Fung KZ, Kirby KA, Shi Y, Espaldon R, O'Brien S, Freedland SJ, Powell AA, Hoffman RM.

JAMA Intern Med. 2013 May 27;173(10):866-73. doi: 10.1001/jamainternmed.2013.323.


Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis: cohort study in the United States.

Fang F, Keating NL, Mucci LA, Adami HO, Stampfer MJ, Valdimarsdóttir U, Fall K.

J Natl Cancer Inst. 2010 Mar 3;102(5):307-14. doi: 10.1093/jnci/djp537. Epub 2010 Feb 2.


Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.

JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720. Erratum in: JAMA. 2011 May 11;305(18):1862.


Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

Items per page

Supplemental Content

Write to the Help Desk